ArticleCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2017
Human papillomavirus in oropharyngeal cancer in Canada: analysis of 5 comprehensive cancer centres using multiple imputation.
Open access · goldAbstract readMulticenter Study
In one paragraph
Article in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
5.9field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Global prevalence of human papillomavirus-related oral and oropharyngeal squamous cell carcinomas: a systematic review and meta-analysis.Clinical oral investigations · 2023Pooled it
- Pooled it
- Prognostic value of the number of imaging-detected lymph node metastases diagnosed by combined FDG-PET/CT and Node-RADS in HPV-associated oropharyngeal carcinoma.European radiology · 2026Article
- Clinical and dosimetric dataset of time-to-event normal tissue complication probability for osteoradionecrosis.Scientific data · 2026Article
- Human papillomavirus (HPV) related oropharyngeal cancers in Canada: A multicenter retrospective cohort study.Human vaccines & immunotherapeutics · 2025Article
- Association of HPV in the Genesis of Head and Neck Squamous Cell Carcinoma: A Case-Control Study in a Bulgarian Cohort.Cancers · 2025Article
- Nutritional characterization of patients with oropharyngeal cancers: impact of human papillomavirus status.European journal of clinical nutrition · 2025Article
- Perceptions of Interprofessional Collaboration in Managing HPV-Related Oropharyngeal Cancer: Implications for Interprofessional Education.Medical science educator · 2025Article
- Prevalence of Oral Human Papillomavirus Infection Among Urban Gay, Bisexual, and Other Men Who Have Sex With Men in Canada, 2017-2019.The Journal of infectious diseases · 2024Article
- Article
- Human Papillomavirus Infection and Oropharyngeal and Gastrointestinal Cancers: A Causal Relationship?Diseases (Basel, Switzerland) · 2022Review
- Unfinished Business in Classifying HPV-Positive Oropharyngeal Carcinoma: Identifying the Bad Apples in a Good Staging Barrel.The oncologist · 2022Article
- Review
- Article
- Clinical variables and magnetic resonance imaging-based radiomics predict human papillomavirus status of oropharyngeal cancer.Head & neck · 2021Article
- Association of Immigration Status and Chinese and South Asian Ethnicity With Incidence of Head and Neck Cancer.JAMA otolaryngology-- head & neck surgery · 2020Article
- Article
- An Occult HPV-Driven Oropharyngeal Squamous Cell Carcinoma Discovered Through a Saliva Test.Frontiers in oncology · 2020Article
- Exploring lay public and dental professional knowledge around HPV transmission via oral sex and oral cancer development.BMC public health · 2019Article
- Human papillomavirus-associated oropharyngeal cancer: review of current evidence and management.Current oncology (Toronto, Ont.) · 2019Review
Corrections and comments
- Commented on by
Authors and funding
15 authors at 3 institutions in 1 country.
Steven HabbousOntario Cancer Institute (Habbous, O'Sullivan, Huang, Liu) and Department of Biostatistics (Xu), Princess Margaret Cancer Centre, Toronto, Ont.; Radiation Oncology (Chu, Belayneh, Parliament), Cross Cancer Institute, Edmonton, Alta.; Department of Oncology (Lau, Hao), University of Calgary, Alberta Health Services, Calgary, Alta.; Department of Oncology (Schorr, Hao), Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alta.; Division of Medical Oncology (Ha, Murray, Snow), Nova Scotia Cancer Centre, Dalhousie University, Halifax, NS; Department of Radiation Oncology (O'Sullivan, Huang), Department of Medicine (Liu) and Department of Epidemiology, Dalla Lana School of Public Health (Liu), University of Toronto, Toronto, Ont.; Medical Oncology (Cheung), BC Cancer Agency, Vancouver, BC geoffrey.liu@uhn.ca steven_habbous@hotmail.com.
Karen P ChuOntario Cancer Institute (Habbous, O'Sullivan, Huang, Liu) and Department of Biostatistics (Xu), Princess Margaret Cancer Centre, Toronto, Ont.; Radiation Oncology (Chu, Belayneh, Parliament), Cross Cancer Institute, Edmonton, Alta.; Department of Oncology (Lau, Hao), University of Calgary, Alberta Health Services, Calgary, Alta.; Department of Oncology (Schorr, Hao), Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alta.; Division of Medical Oncology (Ha, Murray, Snow), Nova Scotia Cancer Centre, Dalhousie University, Halifax, NS; Department of Radiation Oncology (O'Sullivan, Huang), Department of Medicine (Liu) and Department of Epidemiology, Dalla Lana School of Public Health (Liu), University of Toronto, Toronto, Ont.; Medical Oncology (Cheung), BC Cancer Agency, Vancouver, BC.
Harold LauOntario Cancer Institute (Habbous, O'Sullivan, Huang, Liu) and Department of Biostatistics (Xu), Princess Margaret Cancer Centre, Toronto, Ont.; Radiation Oncology (Chu, Belayneh, Parliament), Cross Cancer Institute, Edmonton, Alta.; Department of Oncology (Lau, Hao), University of Calgary, Alberta Health Services, Calgary, Alta.; Department of Oncology (Schorr, Hao), Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alta.; Division of Medical Oncology (Ha, Murray, Snow), Nova Scotia Cancer Centre, Dalhousie University, Halifax, NS; Department of Radiation Oncology (O'Sullivan, Huang), Department of Medicine (Liu) and Department of Epidemiology, Dalla Lana School of Public Health (Liu), University of Toronto, Toronto, Ont.; Medical Oncology (Cheung), BC Cancer Agency, Vancouver, BC.
Melissa SchorrOntario Cancer Institute (Habbous, O'Sullivan, Huang, Liu) and Department of Biostatistics (Xu), Princess Margaret Cancer Centre, Toronto, Ont.; Radiation Oncology (Chu, Belayneh, Parliament), Cross Cancer Institute, Edmonton, Alta.; Department of Oncology (Lau, Hao), University of Calgary, Alberta Health Services, Calgary, Alta.; Department of Oncology (Schorr, Hao), Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alta.; Division of Medical Oncology (Ha, Murray, Snow), Nova Scotia Cancer Centre, Dalhousie University, Halifax, NS; Department of Radiation Oncology (O'Sullivan, Huang), Department of Medicine (Liu) and Department of Epidemiology, Dalla Lana School of Public Health (Liu), University of Toronto, Toronto, Ont.; Medical Oncology (Cheung), BC Cancer Agency, Vancouver, BC.
Mathieos BelaynehOntario Cancer Institute (Habbous, O'Sullivan, Huang, Liu) and Department of Biostatistics (Xu), Princess Margaret Cancer Centre, Toronto, Ont.; Radiation Oncology (Chu, Belayneh, Parliament), Cross Cancer Institute, Edmonton, Alta.; Department of Oncology (Lau, Hao), University of Calgary, Alberta Health Services, Calgary, Alta.; Department of Oncology (Schorr, Hao), Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alta.; Division of Medical Oncology (Ha, Murray, Snow), Nova Scotia Cancer Centre, Dalhousie University, Halifax, NS; Department of Radiation Oncology (O'Sullivan, Huang), Department of Medicine (Liu) and Department of Epidemiology, Dalla Lana School of Public Health (Liu), University of Toronto, Toronto, Ont.; Medical Oncology (Cheung), BC Cancer Agency, Vancouver, BC.
Michael N HaOntario Cancer Institute (Habbous, O'Sullivan, Huang, Liu) and Department of Biostatistics (Xu), Princess Margaret Cancer Centre, Toronto, Ont.; Radiation Oncology (Chu, Belayneh, Parliament), Cross Cancer Institute, Edmonton, Alta.; Department of Oncology (Lau, Hao), University of Calgary, Alberta Health Services, Calgary, Alta.; Department of Oncology (Schorr, Hao), Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alta.; Division of Medical Oncology (Ha, Murray, Snow), Nova Scotia Cancer Centre, Dalhousie University, Halifax, NS; Department of Radiation Oncology (O'Sullivan, Huang), Department of Medicine (Liu) and Department of Epidemiology, Dalla Lana School of Public Health (Liu), University of Toronto, Toronto, Ont.; Medical Oncology (Cheung), BC Cancer Agency, Vancouver, BC.
Scott MurrayOntario Cancer Institute (Habbous, O'Sullivan, Huang, Liu) and Department of Biostatistics (Xu), Princess Margaret Cancer Centre, Toronto, Ont.; Radiation Oncology (Chu, Belayneh, Parliament), Cross Cancer Institute, Edmonton, Alta.; Department of Oncology (Lau, Hao), University of Calgary, Alberta Health Services, Calgary, Alta.; Department of Oncology (Schorr, Hao), Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alta.; Division of Medical Oncology (Ha, Murray, Snow), Nova Scotia Cancer Centre, Dalhousie University, Halifax, NS; Department of Radiation Oncology (O'Sullivan, Huang), Department of Medicine (Liu) and Department of Epidemiology, Dalla Lana School of Public Health (Liu), University of Toronto, Toronto, Ont.; Medical Oncology (Cheung), BC Cancer Agency, Vancouver, BC.
Brian O'SullivanOntario Cancer Institute (Habbous, O'Sullivan, Huang, Liu) and Department of Biostatistics (Xu), Princess Margaret Cancer Centre, Toronto, Ont.; Radiation Oncology (Chu, Belayneh, Parliament), Cross Cancer Institute, Edmonton, Alta.; Department of Oncology (Lau, Hao), University of Calgary, Alberta Health Services, Calgary, Alta.; Department of Oncology (Schorr, Hao), Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alta.; Division of Medical Oncology (Ha, Murray, Snow), Nova Scotia Cancer Centre, Dalhousie University, Halifax, NS; Department of Radiation Oncology (O'Sullivan, Huang), Department of Medicine (Liu) and Department of Epidemiology, Dalla Lana School of Public Health (Liu), University of Toronto, Toronto, Ont.; Medical Oncology (Cheung), BC Cancer Agency, Vancouver, BC.
Shao Hui HuangOntario Cancer Institute (Habbous, O'Sullivan, Huang, Liu) and Department of Biostatistics (Xu), Princess Margaret Cancer Centre, Toronto, Ont.; Radiation Oncology (Chu, Belayneh, Parliament), Cross Cancer Institute, Edmonton, Alta.; Department of Oncology (Lau, Hao), University of Calgary, Alberta Health Services, Calgary, Alta.; Department of Oncology (Schorr, Hao), Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alta.; Division of Medical Oncology (Ha, Murray, Snow), Nova Scotia Cancer Centre, Dalhousie University, Halifax, NS; Department of Radiation Oncology (O'Sullivan, Huang), Department of Medicine (Liu) and Department of Epidemiology, Dalla Lana School of Public Health (Liu), University of Toronto, Toronto, Ont.; Medical Oncology (Cheung), BC Cancer Agency, Vancouver, BC.
Stephanie SnowOntario Cancer Institute (Habbous, O'Sullivan, Huang, Liu) and Department of Biostatistics (Xu), Princess Margaret Cancer Centre, Toronto, Ont.; Radiation Oncology (Chu, Belayneh, Parliament), Cross Cancer Institute, Edmonton, Alta.; Department of Oncology (Lau, Hao), University of Calgary, Alberta Health Services, Calgary, Alta.; Department of Oncology (Schorr, Hao), Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alta.; Division of Medical Oncology (Ha, Murray, Snow), Nova Scotia Cancer Centre, Dalhousie University, Halifax, NS; Department of Radiation Oncology (O'Sullivan, Huang), Department of Medicine (Liu) and Department of Epidemiology, Dalla Lana School of Public Health (Liu), University of Toronto, Toronto, Ont.; Medical Oncology (Cheung), BC Cancer Agency, Vancouver, BC.
Matthew ParliamentOntario Cancer Institute (Habbous, O'Sullivan, Huang, Liu) and Department of Biostatistics (Xu), Princess Margaret Cancer Centre, Toronto, Ont.; Radiation Oncology (Chu, Belayneh, Parliament), Cross Cancer Institute, Edmonton, Alta.; Department of Oncology (Lau, Hao), University of Calgary, Alberta Health Services, Calgary, Alta.; Department of Oncology (Schorr, Hao), Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alta.; Division of Medical Oncology (Ha, Murray, Snow), Nova Scotia Cancer Centre, Dalhousie University, Halifax, NS; Department of Radiation Oncology (O'Sullivan, Huang), Department of Medicine (Liu) and Department of Epidemiology, Dalla Lana School of Public Health (Liu), University of Toronto, Toronto, Ont.; Medical Oncology (Cheung), BC Cancer Agency, Vancouver, BC.
Desiree HaoOntario Cancer Institute (Habbous, O'Sullivan, Huang, Liu) and Department of Biostatistics (Xu), Princess Margaret Cancer Centre, Toronto, Ont.; Radiation Oncology (Chu, Belayneh, Parliament), Cross Cancer Institute, Edmonton, Alta.; Department of Oncology (Lau, Hao), University of Calgary, Alberta Health Services, Calgary, Alta.; Department of Oncology (Schorr, Hao), Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alta.; Division of Medical Oncology (Ha, Murray, Snow), Nova Scotia Cancer Centre, Dalhousie University, Halifax, NS; Department of Radiation Oncology (O'Sullivan, Huang), Department of Medicine (Liu) and Department of Epidemiology, Dalla Lana School of Public Health (Liu), University of Toronto, Toronto, Ont.; Medical Oncology (Cheung), BC Cancer Agency, Vancouver, BC.
Winson Y CheungOntario Cancer Institute (Habbous, O'Sullivan, Huang, Liu) and Department of Biostatistics (Xu), Princess Margaret Cancer Centre, Toronto, Ont.; Radiation Oncology (Chu, Belayneh, Parliament), Cross Cancer Institute, Edmonton, Alta.; Department of Oncology (Lau, Hao), University of Calgary, Alberta Health Services, Calgary, Alta.; Department of Oncology (Schorr, Hao), Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alta.; Division of Medical Oncology (Ha, Murray, Snow), Nova Scotia Cancer Centre, Dalhousie University, Halifax, NS; Department of Radiation Oncology (O'Sullivan, Huang), Department of Medicine (Liu) and Department of Epidemiology, Dalla Lana School of Public Health (Liu), University of Toronto, Toronto, Ont.; Medical Oncology (Cheung), BC Cancer Agency, Vancouver, BC.
Wei XuOntario Cancer Institute (Habbous, O'Sullivan, Huang, Liu) and Department of Biostatistics (Xu), Princess Margaret Cancer Centre, Toronto, Ont.; Radiation Oncology (Chu, Belayneh, Parliament), Cross Cancer Institute, Edmonton, Alta.; Department of Oncology (Lau, Hao), University of Calgary, Alberta Health Services, Calgary, Alta.; Department of Oncology (Schorr, Hao), Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alta.; Division of Medical Oncology (Ha, Murray, Snow), Nova Scotia Cancer Centre, Dalhousie University, Halifax, NS; Department of Radiation Oncology (O'Sullivan, Huang), Department of Medicine (Liu) and Department of Epidemiology, Dalla Lana School of Public Health (Liu), University of Toronto, Toronto, Ont.; Medical Oncology (Cheung), BC Cancer Agency, Vancouver, BC.
Geoffrey LiuOntario Cancer Institute (Habbous, O'Sullivan, Huang, Liu) and Department of Biostatistics (Xu), Princess Margaret Cancer Centre, Toronto, Ont.; Radiation Oncology (Chu, Belayneh, Parliament), Cross Cancer Institute, Edmonton, Alta.; Department of Oncology (Lau, Hao), University of Calgary, Alberta Health Services, Calgary, Alta.; Department of Oncology (Schorr, Hao), Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alta.; Division of Medical Oncology (Ha, Murray, Snow), Nova Scotia Cancer Centre, Dalhousie University, Halifax, NS; Department of Radiation Oncology (O'Sullivan, Huang), Department of Medicine (Liu) and Department of Epidemiology, Dalla Lana School of Public Health (Liu), University of Toronto, Toronto, Ont.; Medical Oncology (Cheung), BC Cancer Agency, Vancouver, BC geoffrey.liu@uhn.ca steven_habbous@hotmail.com.
Dalhousie University · CANova Scotia Cancer Centre · CABC Cancer Agency · CA
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of oropharyngeal cancer has risen over the past 2 decades. This rise has been attributed to human papillomavirus (HPV), but information on temporal trends in incidence of HPV-associated cancers across Canada is limited.
methodsWe collected social, clinical and demographic characteristics and p16 protein status (p16-positive or p16-negative, using this immunohistochemistry variable as a surrogate marker of HPV status) for 3643 patients with oropharyngeal cancer diagnosed between 2000 and 2012 at comprehensive cancer centres in British Columbia (6 centres), Edmonton, Calgary, Toronto and Halifax. We used receiver operating characteristic curves and multiple imputation to estimate the p16 status for missing values. We chose a best-imputation probability cut point on the basis of accuracy in samples with known p16 status and through an independent relation between p16 status and overall survival. We used logistic and Cox proportional hazard regression.
resultsWe found no temporal changes in p16-positive status initially, but there was significant selection bias, with p16 testing significantly more likely to be performed in males, lifetime never-smokers, patients with tonsillar or base-of-tongue tumours and those with nodal involvement (
interpretationAcross multiple centres in Canada, there was a steady rise in the proportion of oropharyngeal cancers attributable to HPV from 2000 to 2012.
Indexed as
AgedBiomarkers, TumorCanadaCarcinoma, Squamous CellCyclin-Dependent Kinase Inhibitor p16Databases, FactualFemaleHuman papillomavirus 16HumansImmunohistochemistryIncidenceLogistic ModelsMaleMiddle AgedMultivariate AnalysisOropharyngeal NeoplasmsBiomarkers, TumorCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.